Lapatinib? or Radiotherapy? In Cranial Metastasis of Breast Cancer.
作者信息
Cihan Yasemin Benderli
机构信息
Department of Radiation Oncology, Kayseri Tarining and Research Hospital, Kayseri, Turkey.
出版信息
Eur J Breast Health. 2019 Jul 1;15(3):205-206. doi: 10.5152/ejbh.2019.4874. eCollection 2019 Jul.
Abstract
摘要
相似文献
1
Lapatinib? or Radiotherapy? In Cranial Metastasis of Breast Cancer.拉帕替尼还是放疗？乳腺癌脑转移的治疗选择
Eur J Breast Health. 2019 Jul 1;15(3):205-206. doi: 10.5152/ejbh.2019.4874. eCollection 2019 Jul.
2
Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer.HER2阳性乳腺癌孤立性脑转移患者接受拉帕替尼再次治疗后的长期生存情况
J Breast Health. 2015 Jan 1;11(1):48-51. doi: 10.5152/tjbh.2014.2009. eCollection 2015 Jan.
3
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.拉帕替尼用于HER2阳性乳腺癌脑转移患者的多中心II期研究。
Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.
4
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.拉帕替尼治疗后曲妥珠单抗再治疗在HER2阳性转移性乳腺癌多次治疗后的应用：一项安纳托利亚医学肿瘤学会研究
Asian Pac J Cancer Prev. 2015;16(9):4127-31. doi: 10.7314/apjcp.2015.16.9.4127.
5
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).拉帕替尼联合全脑放疗治疗乳腺癌和非小细胞肺癌脑转移患者的Ⅱ期研究：希腊肿瘤协作组（HeCOG）的研究。
J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z. Epub 2017 Jul 7.
6
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.一项在人表皮生长因子受体 2（HER2）阳性乳腺癌脑转移患者中应用拉帕替尼联合全脑放疗的 I 期研究。
Breast Cancer Res Treat. 2013 Nov;142(2):405-14. doi: 10.1007/s10549-013-2754-0. Epub 2013 Nov 7.
7
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.接受拉帕替尼联合卡培他滨治疗的HER2阳性脑转移乳腺癌患者的临床结局以及与接受曲妥珠单抗治疗患者的生存比较：安纳托利亚医学肿瘤学会的一项研究
Breast Cancer. 2014 Nov;21(6):677-83. doi: 10.1007/s12282-013-0441-y. Epub 2013 Jan 19.
8
Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.拉帕替尼对人表皮生长因子受体2阳性乳腺癌细胞的放射增敏作用。
Oncotarget. 2016 Nov 29;7(48):79089-79100. doi: 10.18632/oncotarget.12597.
9
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.负载拉帕替尼的人血清白蛋白纳米颗粒用于预防和治疗三阴性乳腺癌脑转移
Oncotarget. 2016 Jun 7;7(23):34038-51. doi: 10.18632/oncotarget.8697.
10
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.拉帕替尼与卡培他滨全口服联合方案用于HER2阳性乳腺癌脑转移患者——一项II期研究
J Egypt Natl Canc Inst. 2014 Dec;26(4):187-94. doi: 10.1016/j.jnci.2014.08.001. Epub 2014 Oct 5.
引用本文的文献
1
A common molecular and cellular pathway in developing Alzheimer and cancer.阿尔茨海默病与癌症发展过程中的一种常见分子和细胞途径。
Biochem Biophys Rep. 2023 Dec 26;37:101625. doi: 10.1016/j.bbrep.2023.101625. eCollection 2024 Mar.
2
EGFR is a potential dual molecular target for cancer and Alzheimer's disease.表皮生长因子受体是癌症和阿尔茨海默病的潜在双重分子靶点。
Front Pharmacol. 2023 Aug 2;14:1238639. doi: 10.3389/fphar.2023.1238639. eCollection 2023.
3
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.载有拉帕替尼的人诱导多能干细胞衍生血小板有效地靶向 HER2+ 乳腺癌脑转移。
Sci Rep. 2021 Oct 15;11(1):16866. doi: 10.1038/s41598-021-96351-2.
4
Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience.乳腺癌脑转移的新兴治疗策略：从转化治疗到真实世界经验
Ther Adv Med Oncol. 2020 Jun 30;12:1758835920936151. doi: 10.1177/1758835920936151. eCollection 2020.
本文引用的文献
1
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.接受靶向治疗的乳腺癌脑转移分子亚型的总生存期及放疗反应
Cancer. 2017 Jun 15;123(12):2283-2293. doi: 10.1002/cncr.30616. Epub 2017 Feb 13.
2
Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?乳腺癌患者的中枢神经系统受累：治疗领域的进展是否过于缓慢？
Cancer Treat Rev. 2016 May;46:80-8. doi: 10.1016/j.ctrv.2016.03.014. Epub 2016 Apr 1.
3
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.曲妥珠单抗为基础的系统治疗和颅放射治疗后 HER2 过表达乳腺癌患者的拉帕替尼治疗脑转移的 II 期研究：日本患者亚组分析。
Int J Clin Oncol. 2013 Aug;18(4):621-8. doi: 10.1007/s10147-012-0444-2. Epub 2012 Jul 19.
4
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.曲妥珠单抗联合卡培他滨治疗 HER2 阳性乳腺癌脑转移患者的临床疗效。
Ann Oncol. 2011 Mar;22(3):625-630. doi: 10.1093/annonc/mdq434. Epub 2010 Aug 19.
5
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.拉帕替尼用于HER2阳性乳腺癌脑转移患者的多中心II期研究。
Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.
6
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.拉帕替尼用于人表皮生长因子受体2阳性乳腺癌患者脑转移的II期试验。
J Clin Oncol. 2008 Apr 20;26(12):1993-9. doi: 10.1200/JCO.2007.12.3588.
7
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.拉帕替尼联合卡培他滨与单用卡培他滨治疗曲妥珠单抗治疗后进展的晚期乳腺癌女性患者的III期随机对照试验：疗效更新及生物标志物分析
Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.
8
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.接受曲妥珠单抗治疗的HER-2阳性转移性乳腺癌患者的中枢神经系统转移：发生率、生存率及危险因素
Oncologist. 2007 Jul;12(7):766-73. doi: 10.1634/theoncologist.12-7-766.
Zotero 插件